We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 12, 2021

Long-Term Effect of Natalizumab in Patients With Relapsing–Remitting Multiple Sclerosis

Multiple Sclerosis (Houndmills, Basingstoke, England)


Additional Info

Multiple Sclerosis (Houndmills, Basingstoke, England)
Long-Term Effect of Natalizumab in Patients With RRMS: TYSTEN Cohort
Mult. Scler. 2021 Apr 01;27(5)729-741, K Bigaut, T Fabacher, L Kremer, JC Ongagna, A Kwiatkowski, F Sellal, D Ferriby, S Courtois, P Vermersch, N Collongues, H Zéphir, J De Seze, O Outteryck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading